This article was originally published in The Gray Sheet
Executive SummaryAllows $110 mil. acquisition offer for U.K.-based Isotron plc to lapse, citing the lack of that firm's shareholder acceptance of the deal, Steris says Aug. 12. First announced July 20, the deal was intended to give Steris a foothold for expansion into the European market (1"The Gray Sheet" July 26, p. 9). Isotron is a provider of sterilization services for single-use medical products. Conditioned on a minimum of 90% Isotron shareholder acceptance of the deal, Steris had received only 60.4% of shareholder acceptances by the Aug. 11 due date. Steris concluded it was "not in the best interests of its shareholders to continue with the offer"
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.